I Sturm

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi [Thromboembolic events, abortions and a sick infant--unusual presentation of a vitamin deficiency]
    I Sturm
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Berlin, Deutschland
    Internist (Berl) 49:1507-11. 2008
  2. ncbi Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy
    Isrid Sturm
    University Medical Center Charite, Campus Virchow Klinikum, Department of Hematology and Oncology, 13353 Berlin, Germany
    BMC Cancer 6:124. 2006
  3. ncbi In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
    Isrid Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Berlin, Germany
    BMC Cancer 5:105. 2005
  4. ncbi Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis
    I Sturm
    Department of Hematology, Oncology and Tumor Immunology, , Humboldt University
    J Clin Oncol 19:2272-81. 2001
  5. ncbi Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma
    S Hermann
    Department of Hematology, Oncology, and Tumor Immunology, , Humboldt University, Berlin-Buch, Germany
    Int J Cancer 92:805-11. 2001
  6. ncbi Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice
    P T Daniel
    Max Delbrück Center for Molecular Medicine the Department of Hematology, Oncology and Tumor Immunology, Charité Campus Berlin Buch, Humboldt University, Berlin Buch, Germany
    Blood 94:1100-7. 1999
  7. ncbi Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
    I Sturm
    Department of Hematology, Oncology and Tumor Immunology, , Humboldt University, 13125 Berlin-Buch, Germany
    Cell Death Differ 10:477-84. 2003
  8. ncbi Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma
    I Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charit, Campus Berlin-Buch, Berlin, Germany
    Cell Death Differ 13:619-27. 2006
  9. ncbi The kiss of death: promises and failures of death receptors and ligands in cancer therapy
    P T Daniel
    Department of Hematology, Oncology, and Tumor Immunology, , Humboldt University, Berlin, Germany
    Leukemia 15:1022-32. 2001
  10. ncbi Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors
    Katharina Schelwies
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Humboldt University, Lindenberger Weg 80, 13125 Berlin Buch, Germany
    Int J Cancer 99:589-96. 2002

Collaborators

Detail Information

Publications16

  1. ncbi [Thromboembolic events, abortions and a sick infant--unusual presentation of a vitamin deficiency]
    I Sturm
    Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Charite, Campus Virchow Klinikum, Berlin, Deutschland
    Internist (Berl) 49:1507-11. 2008
    ..At the age of 5 months, the infant had to be admitted to hospital due to severe vitamin B(12)-deficiency. Using parenteral vitamin B(12) substitution, homocystein levels of the mother normalized and the infant throve and prospered again...
  2. ncbi Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy
    Isrid Sturm
    University Medical Center Charite, Campus Virchow Klinikum, Department of Hematology and Oncology, 13353 Berlin, Germany
    BMC Cancer 6:124. 2006
    ..e. 5-fluorouracil (5-FU), ionising gamma-radiation (IR) and heat shock/hyperthermia...
  3. ncbi In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
    Isrid Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Berlin, Germany
    BMC Cancer 5:105. 2005
    ..Here, we address the functional relevance of the codon 72 single nucleotide (SNP) polymorphism for cell death sensitivity following exposure to clinically employed cytotoxic drugs and gamma-irradiation...
  4. ncbi Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis
    I Sturm
    Department of Hematology, Oncology and Tumor Immunology, , Humboldt University
    J Clin Oncol 19:2272-81. 2001
    ..We suggest that such a multimarker analysis of apoptosis pathways could be useful for individualization of therapeutic strategies in the future, and suggest prospective studies to confirm these results...
  5. ncbi Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma
    S Hermann
    Department of Hematology, Oncology, and Tumor Immunology, , Humboldt University, Berlin-Buch, Germany
    Int J Cancer 92:805-11. 2001
    ..Consequently, the overexpressed p53 might be a correlate for dysregulation without loss of function. This, in turn, might be a reason for the good outcome of some patients with thyroid cancer...
  6. ncbi Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice
    P T Daniel
    Max Delbrück Center for Molecular Medicine the Department of Hematology, Oncology and Tumor Immunology, Charité Campus Berlin Buch, Humboldt University, Berlin Buch, Germany
    Blood 94:1100-7. 1999
    ..The complete suppression of tumor growth in a severe combined immunodeficient mouse xenotransplant model suggests that, in analogy to Bax, Bik/Nbk may function as a tumor suppressor gene...
  7. ncbi Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
    I Sturm
    Department of Hematology, Oncology and Tumor Immunology, , Humboldt University, 13125 Berlin-Buch, Germany
    Cell Death Differ 10:477-84. 2003
    ..This finding may explain at least to some extent the development of resistance to second-line anticancer chemotherapy...
  8. ncbi Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma
    I Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charit, Campus Berlin-Buch, Berlin, Germany
    Cell Death Differ 13:619-27. 2006
    ..These data delineate a role for defects in BH3-only proteins as tumor suppressors in RCC and may explain at the same time the impressive clinical apoptosis resistance of RCC...
  9. ncbi The kiss of death: promises and failures of death receptors and ligands in cancer therapy
    P T Daniel
    Department of Hematology, Oncology, and Tumor Immunology, , Humboldt University, Berlin, Germany
    Leukemia 15:1022-32. 2001
    ....
  10. ncbi Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors
    Katharina Schelwies
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Humboldt University, Lindenberger Weg 80, 13125 Berlin Buch, Germany
    Int J Cancer 99:589-96. 2002
    ..Our study therefore provides the basis for the analysis of defects in p53/BAX (and additional genes) in a prospective trial that is the logical basis for future risk-adapted therapies...
  11. ncbi Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation
    Isrid Sturm
    Department of Hematology and Oncology, Charite, Campus Virchow Medical Center, Humboldt University, Berlin, Germany
    Int J Cancer 118:2329-36. 2006
    ..Nevertheless, a poor prognosis was observed in patients with loss of APAF-1 expression and additional p53 mutation. Thus, loss of APAF-1 may become relevant when additional core apoptosis signaling components are disrupted...
  12. ncbi Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis
    Patricia Grabowski
    Medizinische Klinik I, Gastroenterologie Infektiologie Rheumatologie, Charite Campus Benjamin Franklin, Berlin, Germany
    Int J Colorectal Dis 21:221-30. 2006
    ..Because these markers are involved in different genetic events disrupted in colorectal cancer, we investigated the prognostic power of a multimarker analysis...
  13. ncbi Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy
    Beate Rau
    Charite Medical School, Campus Berlin Buch, Humboldt University, Department of Surgery and Surgical Oncology, Robert Roessle Klinik, Lindenberger Weg 80, 13125 Berlin, Germany
    J Clin Oncol 21:3391-401. 2003
    ..The focus of this study was on the dynamics of these genetic markers in a longitudinal study-that is, before and after radiochemotherapy...
  14. ncbi The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines
    Silke Radetzki
    Department of Hematology, Oncology, and Tumor Immunology, , Humboldt University, 13125 Berlin-Buch, Germany
    Oncogene 21:227-38. 2002
    ..e. efflux-mediated, resistance for drug-induced cell death in the MT3-Adr cell line. Nbk/Bik and Bak could therefore be target genes to increase chemosensitivity and overcome different types of drug resistance...
  15. ncbi Prognostic value of multimarker analysis in stage III colorectal cancer: one step forward towards an individualized therapy decision
    Patricia Grabowski
    Medical Clinic I, Gastroenterology, Infectious Diseases, Rheumatology, , Berlin, Germany
    Onkologie 28:399-403. 2005
    ..The derived discriminant function allows patient stratification according to risk. Therefore, a multimarker analysis provides a rationale for future individualized risk-adapted therapies in stage III colorectal cancer...